Cite
Corrigendum to 'An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature' (Vaccine (2018) 36(21) (3054–3060), (S0264410X1830433X), (10.1016/j.vaccine.2018.03.064))
MLA
“Corrigendum to ‘An Improved Conjugate Vaccine Technology; Induction of Antibody Responses to the Tumor Vasculature’ (Vaccine (2018) 36(21) (3054–3060), (S0264410X1830433X), (10.1016/j.Vaccine.2018.03.064)).” Vaccine, vol. 37, no. 30, July 2019, pp. 4231–32. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dris...00893..33ac24362e44e2d470014f49634a98ff&authtype=sso&custid=ns315887.
APA
Corrigendum to “An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature” (Vaccine (2018) 36(21) (3054–3060), (S0264410X1830433X), (10.1016/j.vaccine.2018.03.064)). (2019). Vaccine, 37(30), 4231–4232.
Chicago
“Corrigendum to ‘An Improved Conjugate Vaccine Technology; Induction of Antibody Responses to the Tumor Vasculature’ (Vaccine (2018) 36(21) (3054–3060), (S0264410X1830433X), (10.1016/j.Vaccine.2018.03.064)).” 2019. Vaccine 37 (30): 4231–32. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dris...00893..33ac24362e44e2d470014f49634a98ff&authtype=sso&custid=ns315887.